

Data Sharing Statement

Guttman-Yassky. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. *JAMA Dermatol*. Published February 26, 2020.

10.1001/jamadermatol.2020.0079

Data

Data available: No

Additional Information

Explanation for why data not available: Dermira shares data related to this trial in peer-reviewed journals, medical congresses, and ClinicalTrials.gov. The study protocol is available as part of the public reporting of this manuscript. Individual patient data are not publicly available.